Clinical trial
Phase III Study of Gemcitabine Compared With UFT in Patients With Completely…
NCT00139971 · West Japan Thoracic Oncology Group, Other · Unknown status
Key facts
| NCT number | NCT00139971 |
|---|---|
| Title | Phase III Study of Gemcitabine Compared With UFT in Patients With Completely Resected Pathological Stage IB-IIIa Non Small Cell Lung Cancer |
| Lead sponsor | West Japan Thoracic Oncology Group, Other |
| Status | Unknown status |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Lung Cancer |
| Intervention type | Drug |
| Interventions | gemicitabine 1000mg/m2, day1 and day 8, every 3 week, 6, UFT 250mg/m2, daily for 1 year |
| Enrollment | 600 |
| Start date | Dec 1, 2001 |
| First posted | Aug 31, 2005 |
| Last update posted | Jan 6, 2006 |
| Countries | Japan |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: